Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review
Background: Asthma is a highly prevalent chronic inflammatory airways disease, with a considerable impact on quality of life (QoL). To express the effects of asthma on patients’ subjective experience, patient-reported outcomes (PROs) represent an important instrument. The asthma QoL questionnaire (A...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-04-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/1753466619841350 |
id |
doaj-e3ac39563b434878ac7ec8c489d6438a |
---|---|
record_format |
Article |
spelling |
doaj-e3ac39563b434878ac7ec8c489d6438a2020-11-25T02:33:59ZengSAGE PublishingTherapeutic Advances in Respiratory Disease1753-46662019-04-011310.1177/1753466619841350Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic reviewGiorgio Lorenzo ColomboSergio Di MatteoChiara MartinottiMartina OselinMaria Chiara ValentinoGiacomo Matteo BrunoClaudia PitottiFrancesco MenzellaBackground: Asthma is a highly prevalent chronic inflammatory airways disease, with a considerable impact on quality of life (QoL). To express the effects of asthma on patients’ subjective experience, patient-reported outcomes (PROs) represent an important instrument. The asthma QoL questionnaire (AQLQ) is one of the main PROs among these. Materials and methods: To identify long-term asthma-related QoL outcomes associated with omalizumab therapy in patients with moderate-to-severe asthma, we developed a systematic review according to the PRISMA guidelines. Published real-world effectiveness studies of adults or adolescents (12 years or older) with moderate-to-severe allergic asthma treated with omalizumab for at least 48 weeks were reviewed. Sources used were Medline ( PubMed ), the Cochrane Library and Google Scholar up to February 2018. In addition, a cross-referencing search was conducted to complete the revision. Results: A total of 255 potential papers were identified in the first search through the database. After full-text viewing, eight articles were finally included in the review. We summarized the results according to the study design, patient baseline characteristics and effectiveness outcomes assessed by AQLQ score results: variation from baseline to the end of study. Results confirmed the long-term benefits of omalizumab as an add-on therapy in patients with uncontrolled moderate-to-severe allergic asthma. Since there is a lot of evidence on omalizumab effectiveness, we aimed to focus on how a therapy can change patient’s QoL in a long time period. Data showed long-term effects of omalizumab treatment on subjective (PROs) and objective (lung function, corticosteroid use, hospitalizations, asthma exacerbation) effectiveness measures. Conclusion: Studies included in our review were observational trials that, due to their design, present a potential risk of selection bias in the patients included. Beyond this limit, the evaluation of QoL using the AQLQ showed a clear increase over time, following both 48 weeks and 9 years of observation, where QoL improvements still were significant over baseline values.https://doi.org/10.1177/1753466619841350 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Giorgio Lorenzo Colombo Sergio Di Matteo Chiara Martinotti Martina Oselin Maria Chiara Valentino Giacomo Matteo Bruno Claudia Pitotti Francesco Menzella |
spellingShingle |
Giorgio Lorenzo Colombo Sergio Di Matteo Chiara Martinotti Martina Oselin Maria Chiara Valentino Giacomo Matteo Bruno Claudia Pitotti Francesco Menzella Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review Therapeutic Advances in Respiratory Disease |
author_facet |
Giorgio Lorenzo Colombo Sergio Di Matteo Chiara Martinotti Martina Oselin Maria Chiara Valentino Giacomo Matteo Bruno Claudia Pitotti Francesco Menzella |
author_sort |
Giorgio Lorenzo Colombo |
title |
Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review |
title_short |
Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review |
title_full |
Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review |
title_fullStr |
Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review |
title_full_unstemmed |
Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review |
title_sort |
omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Respiratory Disease |
issn |
1753-4666 |
publishDate |
2019-04-01 |
description |
Background: Asthma is a highly prevalent chronic inflammatory airways disease, with a considerable impact on quality of life (QoL). To express the effects of asthma on patients’ subjective experience, patient-reported outcomes (PROs) represent an important instrument. The asthma QoL questionnaire (AQLQ) is one of the main PROs among these. Materials and methods: To identify long-term asthma-related QoL outcomes associated with omalizumab therapy in patients with moderate-to-severe asthma, we developed a systematic review according to the PRISMA guidelines. Published real-world effectiveness studies of adults or adolescents (12 years or older) with moderate-to-severe allergic asthma treated with omalizumab for at least 48 weeks were reviewed. Sources used were Medline ( PubMed ), the Cochrane Library and Google Scholar up to February 2018. In addition, a cross-referencing search was conducted to complete the revision. Results: A total of 255 potential papers were identified in the first search through the database. After full-text viewing, eight articles were finally included in the review. We summarized the results according to the study design, patient baseline characteristics and effectiveness outcomes assessed by AQLQ score results: variation from baseline to the end of study. Results confirmed the long-term benefits of omalizumab as an add-on therapy in patients with uncontrolled moderate-to-severe allergic asthma. Since there is a lot of evidence on omalizumab effectiveness, we aimed to focus on how a therapy can change patient’s QoL in a long time period. Data showed long-term effects of omalizumab treatment on subjective (PROs) and objective (lung function, corticosteroid use, hospitalizations, asthma exacerbation) effectiveness measures. Conclusion: Studies included in our review were observational trials that, due to their design, present a potential risk of selection bias in the patients included. Beyond this limit, the evaluation of QoL using the AQLQ showed a clear increase over time, following both 48 weeks and 9 years of observation, where QoL improvements still were significant over baseline values. |
url |
https://doi.org/10.1177/1753466619841350 |
work_keys_str_mv |
AT giorgiolorenzocolombo omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview AT sergiodimatteo omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview AT chiaramartinotti omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview AT martinaoselin omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview AT mariachiaravalentino omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview AT giacomomatteobruno omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview AT claudiapitotti omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview AT francescomenzella omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview |
_version_ |
1724811003411038208 |